PAK4 Inhibition Increases Anti-PD-1 Response in Mouse Models Prompting Phase I Trial

NEW YORK – A new study has identified an apparent role for the PAK4 oncogene in anti-PD-1 checkpoint immunotherapy, prompting a Phase I clinical trial of a PAK4 inhibitor in combination with the PD-1 targeting drug nivolumab (Opdivo from Bristol-Myers Squibb) in around 175 individuals with advanced solid tumors or non-Hodgkin's lymphoma.